First-in-human single ascending dose study supports continued development of LPH-5 toward a scalable at-home treatment for depressive disorders and other neuropsychiatric conditions
Key findings include:
- Favourable safety and tolerability profile
LPH-5 was generally safe and well tolerated across all dose levels tested, with no serious adverse events reported.
- Predictable PK supportive of the subperceptual, long-exposure paradigm
LPH-5 showed predictable, dose-proportional exposure and a human half-life profile aligned with Lophora’s intended sub-perceptual, long-exposure 5-HT2AR treatment paradigm.
- Evidence of dose-dependent CNS pharmacodynamic activity
Quantitative EEG measurements showed dose-dependent CNS activity consistent with engagement of the intended 5-HT2AR-mediated pharmacological pathway.
LPH-5 is a highly selective 5-HT2AR targeting compound designed to deliver sub-perceptual, long-exposure central activity without acute psychedelic effects.
Lophora is engaging with potential partners and investors in connection with BIO 2026 in San Diego, June 22–25, as it prepares for the next stage of LPH-5’s clinical development.